Shahin Huseynov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shahin Huseynov has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
Caroline K. Johannesen
Department of Clinical Research, Nordsjællands Hospital, Hilleroed, Denmark
2 shared publicationsDragan Jankovic
Programm für durch Impfung vermeidbare Krankheiten und Immunisierung, Weltgesundheitsorganisation, Regionalbüro für Europa, 2100, Kopenhagen, Dänemark
2 shared publications- Eugene V. Saxentoff
Vaccine-preventable Diseases and Immunization, Division of Communicable Diseases, Environment and Health, World Health Organization (WHO) Regional Office for Europe, Copenhagen, Denmark
2 shared publications José E. Hagan
Vaccine-preventable Diseases and Immunization, Division of Communicable Diseases, Environment and Health, World Health Organization (WHO) Regional Office for Europe, Copenhagen, Denmark
2 shared publicationsMyriam Ben Mamou
Programm für durch Impfung vermeidbare Krankheiten und Immunisierung, Weltgesundheitsorganisation, Regionalbüro für Europa, 2100, Kopenhagen, Dänemark
2 shared publications- Nino Khetsuriani
Centers for Disease Control and Prevention, Atlanta, USA
2 shared publications
Latest Publications
- Open Access
- 11 June 2026
- Published by Elsevier in The Lancet Primary Care
- Vol. 2 (6)
Primary health care for sustaining immunisation services in a war-affected setting: the experience of Ukraine
- 11 June 2026
- Published by Elsevier in The Lancet Primary Care
- Vol. 2 (6)
Open AccessPrimary health care for sustaining immunisation services in a war-affected setting: the experience of Ukraine
- Open Access
- 11 April 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 53, 101292
Enterovirus circulation in the WHO European region, 2015–2022: a comparison of data from WHO's three core poliovirus surveillance systems and the European Non-Polio Enterovirus Network (ENPEN)
- 11 April 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 53, 101292
Open AccessEnterovirus circulation in the WHO European region, 2015–2022: a comparison of data from WHO's three core poliovirus surveillance systems and the European Non-Polio Enterovirus Network (ENPEN)
- Open Access
- 19 October 2024
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 47, 101104
Poliovirus circulation in the WHO European region, 2015–2022: a review of data from WHO's three core poliovirus surveillance systems
- 19 October 2024
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 47, 101104
Open AccessPoliovirus circulation in the WHO European region, 2015–2022: a review of data from WHO's three core poliovirus surveillance systems
- 5 August 2020
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 17 (2) , 503-509
Rotavirus vaccine effectiveness and impact in Uzbekistan, the first country to introduce in central Asia
Uzbekistan, the most populous country in central Asia, was the first in the region to introduce rotavirus vaccine into its national immunization program. Rotarix (GlaxoSmithKline Biologicals, RV1) was introduced in June 2014, with doses recommended at age 2 and 3 months. To evaluate vaccine impact, active surveillance for rotavirus diarrhea was reestablished in 2014 at 2 hospitals in Tashkent and Bukhara which had also performed surveillance during the pre-vaccine period 2005−2009. Children aged p <.001). Vaccine effectiveness of 2 RV1 doses vs 0 doses in protecting against hospitalization for rotavirus disease among those aged ≥6 months was 51% (95% CI 2–75) and is based on cases predominantly of genotype G2P[4]. Vaccine effectiveness point estimates tended to be higher against cases with higher illness severity (e.g., clinical severity based on modified Vesikari score ≥11). Our data demonstrate that the monovalent rotavirus vaccine is effective in reducing the likelihood of hospitalization for rotavirus disease in young children in Uzbekistan.
- 5 August 2020
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 17 (2) , 503-509
Rotavirus vaccine effectiveness and impact in Uzbekistan, the first country to introduce in central Asia
Uzbekistan, the most populous country in central Asia, was the first in the region to introduce rotavirus vaccine into its national immunization program. Rotarix (GlaxoSmithKline Biologicals, RV1) was introduced in June 2014, with doses recommended at age 2 and 3 months. To evaluate vaccine impact, active surveillance for rotavirus diarrhea was reestablished in 2014 at 2 hospitals in Tashkent and Bukhara which had also performed surveillance during the pre-vaccine period 2005−2009. Children aged p <.001). Vaccine effectiveness of 2 RV1 doses vs 0 doses in protecting against hospitalization for rotavirus disease among those aged ≥6 months was 51% (95% CI 2–75) and is based on cases predominantly of genotype G2P[4]. Vaccine effectiveness point estimates tended to be higher against cases with higher illness severity (e.g., clinical severity based on modified Vesikari score ≥11). Our data demonstrate that the monovalent rotavirus vaccine is effective in reducing the likelihood of hospitalization for rotavirus disease in young children in Uzbekistan.
- 18 March 2019
- Published by Springer Nature in Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz
- Vol. 62 (4) , 440-449
Eliminierung der Masern aus der Europäischen Region der WHO – Herausforderungen bleiben
Die Maserninzidenz in den 53 Mitgliedstaaten der Europäischen Region der Weltgesundheitsorganisation (WHO) ist in den vergangenen Jahrzehnten drastisch zurückgegangen. Die Verifizierungskommission der Europäischen Region für die Eliminierung der Masern und Röteln (RVC) stellte fest, dass Ende 2017 in 43 Mitgliedstaaten eine endemische Übertragung der Masern seit zwölf Monaten oder länger nicht mehr stattgefunden hatte. Allerdings nahm die Maserninzidenz in der Region 2018 im Vergleich zu 2017 stark zu. Dieser Beitrag bewertet den aktuellen Stand in Bezug auf das Ziel, Masern in der Region zu eliminieren. Es werden Überlegungen zu Herausforderungen und Maßnahmen dieses Ziel zu erreichen angestellt.
- 18 March 2019
- Published by Springer Nature in Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz
- Vol. 62 (4) , 440-449
Eliminierung der Masern aus der Europäischen Region der WHO – Herausforderungen bleiben
Die Maserninzidenz in den 53 Mitgliedstaaten der Europäischen Region der Weltgesundheitsorganisation (WHO) ist in den vergangenen Jahrzehnten drastisch zurückgegangen. Die Verifizierungskommission der Europäischen Region für die Eliminierung der Masern und Röteln (RVC) stellte fest, dass Ende 2017 in 43 Mitgliedstaaten eine endemische Übertragung der Masern seit zwölf Monaten oder länger nicht mehr stattgefunden hatte. Allerdings nahm die Maserninzidenz in der Region 2018 im Vergleich zu 2017 stark zu. Dieser Beitrag bewertet den aktuellen Stand in Bezug auf das Ziel, Masern in der Region zu eliminieren. Es werden Überlegungen zu Herausforderungen und Maßnahmen dieses Ziel zu erreichen angestellt.
- Open Access
- 30 June 2017
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 216 (suppl_1) , S146-S151
Acceptance of the Administration of Multiple Injectable Vaccines in a Single Immunization Visit in Albania
Albania introduced inactivated polio vaccine (IPV) into its immunization system in May 2014, increasing the maximum recommended number of injectable vaccines given in a single visit from 2 to 3. Health-care providers and caregivers were interviewed at 42 health facilities in Albania to assess knowledge, attitudes, and practices regarding injectable vaccine administration. Immunization register data were abstracted from December 2014 to July 2015 at the same facilities to explore the number of injectable vaccines children received during their 2- and 4-month visits. The majority of children (87%) identified in the record review at either their 2- or 4-month immunization visit received all 3 injectable vaccines in a single visit. Almost all children who did not receive the vaccines in a single visit were subsequently fully immunized, most within a 2-week period. Over half of caregivers whose children got 3 or more injectable vaccines in a single visit reported being only comfortable with 1 or 2 injectable vaccines in a single visit. Despite most caregivers expressing hesitation regarding children receiving multiple injectable vaccines in a single visit, most children received vaccines according to the recommended schedule. Almost all children eventually received all recommended vaccines.
- 30 June 2017
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 216 (suppl_1) , S146-S151
Open AccessAcceptance of the Administration of Multiple Injectable Vaccines in a Single Immunization Visit in Albania
Albania introduced inactivated polio vaccine (IPV) into its immunization system in May 2014, increasing the maximum recommended number of injectable vaccines given in a single visit from 2 to 3. Health-care providers and caregivers were interviewed at 42 health facilities in Albania to assess knowledge, attitudes, and practices regarding injectable vaccine administration. Immunization register data were abstracted from December 2014 to July 2015 at the same facilities to explore the number of injectable vaccines children received during their 2- and 4-month visits. The majority of children (87%) identified in the record review at either their 2- or 4-month immunization visit received all 3 injectable vaccines in a single visit. Almost all children who did not receive the vaccines in a single visit were subsequently fully immunized, most within a 2-week period. Over half of caregivers whose children got 3 or more injectable vaccines in a single visit reported being only comfortable with 1 or 2 injectable vaccines in a single visit. Despite most caregivers expressing hesitation regarding children receiving multiple injectable vaccines in a single visit, most children received vaccines according to the recommended schedule. Almost all children eventually received all recommended vaccines.
- Open Access
- 1 February 2016
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 35 (2) , 322-326
Slow Progress In Finalizing Measles And Rubella Elimination In The European Region
All countries in the World Health Organization European Region committed to eliminating endemic transmission of measles and rubella by 2015, and disease incidence has decreased dramatically. However, there was little progress between 2012 and 2013, and the goal will likely not be achieved on time. Genuine political commitment, increased technical capacity, and greater public awareness are urgently needed, especially in Western Europe.
- 1 February 2016
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 35 (2) , 322-326
Open AccessSlow Progress In Finalizing Measles And Rubella Elimination In The European Region
All countries in the World Health Organization European Region committed to eliminating endemic transmission of measles and rubella by 2015, and disease incidence has decreased dramatically. However, there was little progress between 2012 and 2013, and the goal will likely not be achieved on time. Genuine political commitment, increased technical capacity, and greater public awareness are urgently needed, especially in Western Europe.